--- title: "Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's Why" description: "Eledon Pharmaceuticals (NASDAQ:ELDN) shares fell 3.4% to $4.01 during trading, with a volume increase of 49% from the average. Analysts have set price targets, with HC Wainwright maintaining a \"buy\" r" type: "news" locale: "en" url: "https://longbridge.com/en/news/230601241.md" published_at: "2025-03-05T05:52:30.000Z" --- # Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's Why > Eledon Pharmaceuticals (NASDAQ:ELDN) shares fell 3.4% to $4.01 during trading, with a volume increase of 49% from the average. Analysts have set price targets, with HC Wainwright maintaining a "buy" rating at $16.00, while Guggenheim set a $9.00 target. Institutional investors hold 56.77% of the stock. Eledon focuses on immunology to develop therapies for organ transplant protection and ALS treatment. Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report)'s share price dropped 3.4% during trading on Monday . The company traded as low as $3.96 and last traded at $4.01. Approximately 395,521 shares traded hands during mid-day trading, an increase of 49% from the average daily volume of 265,548 shares. The stock had previously closed at $4.15. Get **Eledon Pharmaceuticals** alerts: ## Analysts Set New Price Targets ELDN has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th. Guggenheim started coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a "buy" rating and a $9.00 price target for the company. **Check Out Our Latest Research Report on ELDN** ## Eledon Pharmaceuticals Price Performance The company has a market cap of $239.55 million, a price-to-earnings ratio of -2.00 and a beta of 0.79. The firm's fifty day moving average price is $4.35 and its 200-day moving average price is $3.79. ## Hedge Funds Weigh In On Eledon Pharmaceuticals Several hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $14,693,000. First Light Asset Management LLC acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $8,075,000. Sphera Funds Management LTD. lifted its holdings in Eledon Pharmaceuticals by 96.7% in the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after purchasing an additional 1,254,298 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $4,848,000. Institutional investors and hedge funds own 56.77% of the company's stock. ## About Eledon Pharmaceuticals (Get Free Report) Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). ## Featured Stories - Five stocks we like better than Eledon Pharmaceuticals - Market Cap Calculator: How to Calculate Market Cap - Bearish Investors Can Seek Refuge in Recession-Resistant ETFs - How to Calculate Retirement Income: MarketBeat’s Calculator - 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now? - Airline Stocks - Top Airline Stocks to Buy Now - 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Eledon Pharmaceuticals Right Now? Before you consider Eledon Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list. While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ELDN.US - Eledon Pharmaceuticals](https://longbridge.com/en/quote/ELDN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Eledon Pharmaceuticals 在会议上重点介绍了 BESTOW 数据、III 期计划以及 “Tego” 的 FDA 时间表 | Eledon Pharmaceuticals（纳斯达克代码：ELDN）高管展示了来自 II 期 BESTOW 肾脏移植研究的数据，并概述了他们的研究治疗 “tego” 的 III 期试验计划。尽管肾功能的主要终点未能达到，但管理层强调了与标 | [Link](https://longbridge.com/en/news/275931982.md) | | Eledon Pharmaceuticals 报告 Tegoprubart 在肾移植患者中 24 个月的 1b 期数据表现积极 | Eledon Pharmaceuticals Inc. 将于 2026 年 1 月 23 日至 25 日在美国移植外科医师学会冬季研讨会上展示针对肾脏移植患者的 tegoprubart 的 1b 期试验的 24 个月随访数据。数据显示没有急 | [Link](https://longbridge.com/en/news/273657767.md) | | Telix Pharmaceuticals 的 GAAP 每股收益为-2.11 美元，比预期低 2.14 美元，收入为 8.038 亿美元，比预期少 2279 万美元 | Telix Pharmaceuticals GAAP 每股收益为 -$2.11，低于预期 $2.14，收入为 $803.8M，低于预期 $22.79M | [Link](https://longbridge.com/en/news/276390774.md) | | Baader Bank Aktiengesellschaft 出售了 54,069 股纳斯达克公司（Nasdaq, Inc.）的股票，股票代码为$NDAQ | Baader Bank Aktiengesellschaft 在第三季度将其在纳斯达克公司的持股减少了 86.5%，出售了 54,069 股，剩余 8,450 股，价值 74.5 万美元。其他机构投资者也调整了他们在纳斯达克的持仓。该股票开 | [Link](https://longbridge.com/en/news/275735016.md) | | Recursion Pharmaceuticals（NASDAQ:RXRX）在内部人士抛售后股价下跌 5% | Recursion Pharmaceuticals (NASDAQ:RXRX) 的股价下跌了 5%，因为首席财务官 Ben R. Taylor 以每股 3.08 美元的价格出售了 13,426 股，总计 41,352.08 美元。该股票最低 | [Link](https://longbridge.com/en/news/276459764.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.